Alzheimer’s Drugs Take Baby Steps Toward Brighter Future
Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.
You may also be interested in...
Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
In a rare move, South Korea's Daehwa Pharm is progressing the development of a herbal-derived therapy for Alzheimer's disease, a sector where many pharma firms have been conducting R&D but have faced challenges and failures.